Abstract 1490P
Background
Cancer is a debilitating disease that affects both patients and their caregivers. The diagnosis and treatment of cancer could affect the quality life of the patient and their family. Patients undergoing chemotherapy experience physical and emotional symptoms that affect their quality of life. Some of them experienced difficulty sleeping, depression and poor quality of life. Caregivers of cancer patients may have to cope with a variety of physical, social, and economic problems during the caregiving process. Caregivers experienced caregiver strain while providing care for the patient. The caregiver strain influences the quality of care and thus the quality of life of the patient. Hence, this study aims to determine the health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain.
Methods
A cross sectional analytical study was conducted among cancer patients and their caregiver at the Bataan General Hospital and Medical Center. The EORTC core quality of life questionnaire (QLQ-C30) and modified caregiver strain index (MCSI) questionnaires were administered to assess HRQoL and caregiver strain respectively. Descriptive statistics, Pearson correlation and Spearman rank were performed for analysis of quality-of-life parameters and caregiver strain.
Results
A total of 145 cancer patient-caregiver dyads were included in this study. The median global health status among cancer patients was 75 (66.67 to 91.67) suggesting an optimistic view of overall health and quality of life. The median MCSI score was 19 (14 to 24) indicating a moderate to high level of strain. The relationship between health-related quality of life and caregiver strain showed minimal to no meaningful relationship.
Conclusions
Cancer patients generally exhibit satisfactory to high functioning across physical, role, and cognitive functions. The caregiving role, irrespective of the patient's condition, carries intrinsic challenges. Although the relationship between the HRQoL of patients and caregiver strain was very weak, both are important and functions independently.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10